A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > TRENDS
TRENDS
-
Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade
November 15, 2018
-
Hep C Market Shrinking towards Disease Elimination in 2030
October 12, 2018
-
“Follow-On” Authorized Generics Gaining Ground in Matured Gx Markets; TS-1 Grabs 80% Share
September 4, 2018
-
Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos
August 8, 2018
-
As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
July 13, 2018
-
Japan Drug Makers Downsizing Parent Companies; Takeda Sheds Over 1,000 People in Divestitures, R&D Rejig
July 3, 2018
-
Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
-
Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
May 31, 2018
-
Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom
May 21, 2018
-
Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
April 20, 2018
-
Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers
April 3, 2018
-
Lilly Japan Joins Top 10 List for 1st Time, Sales Triple in 10 Years on Successive Launches
March 30, 2018
-
Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
March 13, 2018
-
Countering Abilify Cliff, Otsuka Sees New Drug Franchise Set Stage for Growth Path
February 23, 2018
-
With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
February 8, 2018
-
Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well
November 22, 2017
-
21 Drug Makers Expect 1.6% Increase in Sales but Decline in Profits in FY2017
November 15, 2017
-
Japan’s “NDB” Insurance Claim Database Corroborates Slack SGLT-2 Prescriptions for Older People in FY2015
September 26, 2017
-
Japan’s 1st DPP-4/SGLT-2 Pair to Hit Shelves Shortly, Will Shift to Combo Drugs Gain Ground?
September 5, 2017
-
Japan Generic Market Decelerating, 3 Majors Log Only Slight Uptick in April-June
August 22, 2017
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…